Q-omics provides the consensus-scored ZBTB43 profile across patient tissues and cancer cell-line models. ZBTB43 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZBTB43 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, ZBTB43 RNA expression shows 20,776 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where ZBTB43 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB43 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB43 survival associations across molecular data types. ZBTB43 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB43 RNA expression–survival associations across cancer types. High ZBTB43 expression shows unfavorable associations in ACC, HNSC and BLCA, but favorable associations in THYM, SCLC and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZBTB43 RNA expression.
This table summarizes ZBTB43 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB43. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB43 shows lower tumor expression in KIRC and higher tumor expression in HNSC, KIRP, KICH, CHOL and BLCA. The HNSC box plot shows higher ZBTB43 RNA expression in tumor versus normal tissue (log2 FC = +0.476, t-test p < 0.001).
This table shows molecular features associated with ZBTB43 in patient tissues and cancer cell lines. In patient samples, ZBTB43 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB43 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
